FMP

FMP

Enter

CRTX - Cortexyme, Inc.

Profile of Cortexyme, Inc.(CRTX), Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for

About

ceo

Ms. Casey Lynch

sector

Healthcare

industry

Biotechnology

website

https://www.cortexyme.com

exchange

NASDAQ

Description

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

CIK

0001662774

ISIN

US22053A1079

CUSIP

22053A107

Address

269 E Grand Ave

Phone

14159105717

Country

US

Employee

55

IPO Date

May 9, 2019

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep